Extended Application of Intraoperative Parathyroid Scores System(IPSS) in Thyroidectomy (IPSS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: BO WANG, MS
- Phone Number: 13705947900
- Email: wangbo@fjmu.edu.cn
Study Locations
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Recruiting
- Wen-xin ZHAO
-
Contact:
- Bo WANG, MS
- Phone Number: 8613705947900
- Email: wangbo@fjmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- postoperative pathology confirmed as thyroid papillary carcinoma;
- for the first time to undergo thyroid surgery, no history of neck surgery and external radiotherapy;
- preoperative serum calcium, parathyroid hormone levels were normal;
- intraoperative and postoperative clinical data integrity, standardized follow-up patients;
- parathyroid is a tumor violation.
Exclusion Criteria:
- serious underlying disease;
- age greater than 60 years of age or combined with arteriosclerotic disease;
- patients with postoperative loss;
- patients with parathyroid disease.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
with IPSS record/IPSS
the surgoen use the IPSS in all thyroidectomy
|
all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary.
record the parathyroid status in verbal description
|
|
Traditionaldescription Group/TD
the surgoen without the IPSS,use Traditional description
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences of parathyroid records between IPSS and TD
Time Frame: 1 year
|
The percentage of recorded integrity of the parathyroid gland and the number of recognizable parathyroids were compared between the two groups.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effect of IPSS on the level of parathyroid recognition of surgeons
Time Frame: 1 year
|
Comparison of the number of parathyroid gland found in the pathology and the number of postoperative hypoparathyroidism between the two groups
|
1 year
|
|
differences of the number of parathyroid glands found in the pathology betwen IPSS and TD
Time Frame: 1 year
|
differences of the number of parathyroid glands found in the pathology betwen IPSS and TD
|
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Predictive Value of IPSS for Intravenous and Oral Calcium duration
Time Frame: 1 year
|
Comparison of the correlation between IPSS values and intravenous calcium supplementation and oral calcium supplementation time.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- IPSS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intraoperative Parathyroid Scores System
-
NCT03172312CompletedIntraoperative Parathyroid Scores System
-
NCT04560426UnknownThyroid Cancer | Parathyroid | Intraoperative Monitoring
-
NCT04697277UnknownIntraoperative Nausea-retching-vomiting Episodes | Nausea Scores Will be Evaluated on the Verbal Analog Scale (VAS)
-
NCT06288750RecruitingIndocyanine Green | Total Thyroidectomy | Parathyroid Function Low Adverse Event | Parathyroid Glands--Diseases
-
NCT03039439RecruitingPrimary Hyperparathyroidism | Parathyroid Gland Carcinoma | Parathyroid Gland Adenoma | Parathyroid Gland Atypical Adenoma
-
NCT07475780RecruitingRecurrent Parathyroid Carcinoma
-
NCT01539486Completed
-
NCT07218224AvailableParathyroid Adenomas
-
NCT01545622Completed
Clinical Trials on with IPSS
-
NCT04870749Completed
-
NCT03486639UnknownOveractive Bladder Syndrome | Bladder Outlet Obstruction | Benign Prostate Enlargement | Stress Incontinence (Female) (Male) | Bladder Disease
-
NCT03603821UnknownLower Urinary Tract Symptoms
-
NCT06362577RecruitingLocalized Prostate Cancer
-
NCT00316732Completed
-
NCT01250483CompletedBenign Prostatic Hyperplasia | Prostate Cancer
-
NCT00002187CompletedHIV Infections | Cytomegalovirus Retinitis
-
NCT04722458CompletedLower Urinary Tract Symptoms | Urinary Incontinence
-
NCT02053805UnknownLynch Syndrome | BRCA1 Syndrome | BRCA2 Syndrome
-
NCT02757963Completed